Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Dimethyl Fumarate (Tecfidera): A New Oral Agent for Multiple Sclerosis.
Telehealth weight management intervention for adults with physical disabilities: a randomized controlled trial.
Reduction in the free radical status and clinical benefit of repeated intrathecal triamcinolone acetonide application in patients with progressive multiple sclerosis.
Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis.
Neurodegenerative Diseases: from available treatments to prospective herbal therapy.
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?
Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up.
[Diagnosis and treatment of neuromyelitis optica.]
Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Processing speed and working memory training in multiple sclerosis: A double-blind randomized controlled pilot study.
Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
Experience of gratitude, awe and beauty in life among patients with multiple sclerosis and psychiatric disorders.
Developmentally regulated GTP-binding protein 2 ameliorates EAE by suppressing the development of TH17 cells.
Inter-hemispheric functional connectivity changes with corpus callosum morphology in multiple sclerosis.
Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients.
Anticomplement therapy.
Genomic Characterization of Japanese Macaque Rhadinovirus: A Novel Herpesvirus Isolated from a Nonhuman Primate with a Spontaneous Inflammatory Demyelinating Disease.
Epileptic seizures in multiple sclerosis: a population-based survey in Iran.
Quantitative MRI demonstrates abnormality of the fornix and cingulum in multiple sclerosis.
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Assessment of urinary incontinence in the women in Eastern Turkey.
Testing different ICA algorithms and connectivity analyses on MS patients.
The role of optical coherence tomography (OCT) in optic neuritis (ON).
Two demyelinating diseases in the brain of a single patient, PML and MS: how to minimize 'one' while treating the 'other'.
Pages
« first
‹ previous
…
434
435
436
437
438
439
440
441
442
…
next ›
last »